Jagsonpal Pharmaceuticals Limited

JAGSNPHARMNotably above fair value

A 6-pillar fundamental profile. Each pillar scored 0–10.

6.6/10 composite
Prism for JAGSNPHARM.NS: composite 6.6 of 10, verdict Notably above fair valuePULSEQUALITYMOATSAFETYGROWTHVALUEBelow cohort range—6.38.08.96.4Below cohort range—

Pulse

— · Neutral

Pulse data unavailable; neutral placeholder

Pulse tracks recent momentum in price, analyst revisions, and news sentiment. Higher means more positive near-term tailwinds.

Quality

6.3 · Moderate

Piotroski 4/9, ROCE 28.1%

Quality captures profitability, return on capital, and earnings consistency. Higher means a better business.

Moat

8.0 · Strong

Wide moat

Moat estimates durable competitive advantages — brand, scale, switching costs. Higher means more defensible.

Safety

8.9 · Strong

D/E 0.03, Int cov 73.8x

Safety looks at balance-sheet quality, leverage, and cash generation. Higher means lower financial risk.

Growth

6.4 · Moderate

Rev CAGR 6.7%, EPS CAGR 9.1%

Growth reflects revenue and earnings expansion over recent years. Higher means faster compounding.

Value

— · Insufficient peer data

Only 0 MoS peers in cohort

Value measures how the stock's price compares to its intrinsic worth. Higher means more discount to fair value.

Compare with another stock

Overlay JAGSNPHARM's prism against a peer.

Share this prism

Share on XWhatsApp

Get the full analysis

Interactive DCF, sensitivity, peer comparison, and AI summary for JAGSNPHARM.

Full analysis →

Model estimate. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.